nach oben

Rheumatology International

Erschienen in:

15.05.2020 | COVID-19 | Correspondence Zur Zeit gratis

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

verfasst von: Erkan Cure, Adem Kucuk, Medine Cumhur Cure

Erschienen in: Rheumatology International | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, Lim DH (2020) Coronavirus disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. Rheumatol Int. https://doi.org/10.1007/s00296-020-04584-7 CrossRefPubMedPubMedCentral

Georgiev T (2020) Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int 40:825–826. https://doi.org/10.1007/s00296-020-04570-z CrossRefPubMedPubMedCentral

Chighizola CB, Ong VH, Meroni PL (2017) The use of cyclosporine a in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol 52:401–423. https://doi.org/10.1007/s12016-016-8582-3 CrossRefPubMed

Carbajo-Lozoya J, Ma-Lauer Y, Malešević M et al (2014) Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res 184:44–53. https://doi.org/10.1016/j.virusres.2014.02.010 CrossRefPubMedPubMedCentral

Russell B, Moss C, George G, Santaolalla A et al (2020) Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 14:1022. https://doi.org/10.3332/ecancer.2020.1022 CrossRefPubMedPubMedCentral

de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y et al (2011) Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 92:2542–2548. https://doi.org/10.1099/vir.0.034983-0 CrossRefPubMedPubMedCentral

Cure E, Cumhur Cure M (2020) Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr 14:405–406. https://doi.org/10.1016/j.dsx.2020.04.024 CrossRefPubMedPubMedCentral

Dixon DB, Takahashi K, Bieda M, Copenhagen DR (1996) Quinine, intracellular pH and modulation of hemi-gap junctions in catfish horizontal cells. Vis Res 36:3925–3931CrossRefPubMed

Forsse A, Nielsen TH, Nygaard KH, Nordström CH, Gramsbergen JB, Poulsen FR (2019) Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia. Sci Rep 9:3702. https://doi.org/10.1038/s41598-019-40245-x CrossRefPubMedPubMedCentral

10.

Epting T, Hartmann K, Sandqvist A, Nitschke R, Gordjani N (2006) Cyclosporin A stimulates apical Na⁺/H⁺ exchange in LLC-PK1/PKE20 proximal tubular cells. Pediatr Nephrol 21:939–946CrossRefPubMed

11.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0 CrossRefPubMedPubMedCentral

12.

Behrens EM, Koretzky GA (2017) Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol 69:1135–1143. https://doi.org/10.1002/art.40071 CrossRefPubMed

13.

Elgebaly SA, Elbayoumi T, Kreutzer DL (2017) Cyclosporin H: a novel anti-inflammatory therapy for influenza flu patients. J Egypt Soc Parasitol 47:25–33PubMed

14.

Palau V, Riera M, Soler MJ (2020) ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa093 CrossRefPubMed

15.

Akool ES, Gauer S, Osman B et al (2012) Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling. Biochem Pharmacol 83:286–295. https://doi.org/10.1016/j.bcp.2011.11.001 CrossRef

16.

Campana C, Regazzi MB, Buggia I, Molinaro M (1996) Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 30:141–179CrossRefPubMed

17.

Perico L, Benigni A, Remuzzi G (2020) Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. https://doi.org/10.1159/000507305 CrossRefPubMed

Titel: Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)
verfasst von: Erkan Cure
Adem Kucuk
Medine Cumhur Cure
Publikationsdatum: 15.05.2020
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: Rheumatology International / Ausgabe 7/2020
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04603-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

A retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?

A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3

Tocilizumab treatment in Felty’s syndrome

Burden and management of gout in a multi-ethnic Asian cohort

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Quality of life in children suffering from juvenile idiopathic arthritis-associated uveitis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin